Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | QDPR | P09417 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29769963 | 0.72 | CASP1 (0.37) | DRD3HRH3 | |
| SCHEMBL30025550 | 0.72 | ADRA2A (0.34) | — | |
| SCHEMBL9573203 | 0.72 | CYP19A1 (0.33) | — | |
| Hydrochloric Acid SCHEMBL11820690 | 0.70 | ADRA2A (0.33) | — | |
| SCHEMBL2299154 | 0.69 | HDAC1 (0.33) | EPHX2QDPRHDAC1HDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL587644 | 0.68 | DHFR (0.32) | — | |
| SCHEMBL30564302 | 0.68 | PDE3B (0.42) | QDPRHRH3 | |
| SCHEMBL29582168 | 0.68 | ALDH1A1 (0.34) | — | |
| SCHEMBL5542873 | 0.68 | CYP11B1 (0.49) | DRD3 | |
| SCHEMBL56690 | 0.66 | TRPA1 (0.42) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220041561-A1 | Amino Pyrimidine Derivatives | NOVARTIS AG (CH) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041561-A1 | Amino Pyrimidine Derivatives | BTK, LCK, JAK1 | EPHX2 3005/4885QDPR 1026/4885HDAC1 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.